益生菌辅助防治化疗相关性腹泻的Meta分析

发布时间：2018-04-19 21:50

  本文选题：化疗相关性腹泻 + 益生菌　； 参考：《中国药房》2017年09期

【摘要】：目的:系统评价益生菌辅助防治化疗相关性腹泻(CID)的有效性,为临床提供循证参考。方法:计算机检索EMBase、Cochrane图书馆、Pub Med、相关期刊论文、中文科技期刊数据库、万方数据库和中国生物医学文献数据库,收集益生菌辅助防治CID的随机对照试验(RCT),提取资料并根据Cochrane Hand book 5.0推荐的"风险偏倚评估"工具评价质量,采用Rev Man5.2统计软件进行Meta分析。结果:最终纳入10项RCT,共871例患者。Meta分析结果显示,在常规对症治疗的基础上加用益生菌可以显著降低肿瘤患者总腹泻率[OR=0.31,95%CI(0.20,0.49),P0.001]和Ⅲ~Ⅳ级腹泻率[OR=0.09,95%CI(0.03,0.24),P0.001],提高总有效率[OR=4.16,95%CI(2.40,7.23),P0.001]和完全缓解率[OR=2.55,95%CI(1.66,3.90),P0.001],差异均有统计学意义;但对患者Ⅰ~Ⅱ级腹泻率[OR=0.86,95%CI(0.48,1.56),P=0.62]和部分缓解率[OR=1.00,95%CI(0.67,1.50),P=1.00]影响不大,差异均无统计学意义。结论:化疗前使用益生菌可有效预防肿瘤患者严重CID的发生;在治疗CID中,联用益生菌亦可以提高常规对症治疗的疗效。
[Abstract]:Objective: to evaluate the efficacy of probiotics in the prevention and treatment of chemotherapy-associated diarrhea. Methods: a computer-based search was conducted for Pub Med, Chinese Journal Full-text Database, Chinese Sci-tech Journal Database, Wanfang Database and Chinese Biomedical Literature Database. A randomized controlled trial of probiotics assisted control of CID was collected. The data were extracted and evaluated according to the "risk bias assessment" tool recommended by Cochrane Hand book 5.0. Meta analysis was carried out with Rev Man5.2 statistical software. Results: a total of 871 patients were included in 10 RCTs. Meta-analysis showed that, However, there was no significant difference in the rates of 鈪，

本文编号：1774876